- Development and validation of a bioelectronic diagnostic device and assays focused on public health threats, including COVID-19, influenza, tuberculosis, and sexually transmitted infections- Propelled this rapid diagnostic technology from innovative concept to working prototype; now establishing planning and partnerships for large-scale manufacturing, assembly, and packaging, in compliance with GMP and FDA-recommended guidelines for medical device manufacture and over-the-counter sales- Oversee investor relationships and funding, raising $2 million- Direct scientific and regulatory activities, including assay verification, clinical trials, and FDA approval- Manage strategic relationships, business development, and collaborations with academia and USG

Pinpoint Science has developed a 30-second, remarkably specific and highly sensitive nanosensor-based antigen test to detect the presence of SARS-CoV-2 in clinical specimens. Accurate, affordable and easy to use, Pinpoint's COVID-19 test detects the SARS-CoV-2 viral proteins from swab and saliva samples. Results are displayed in 30 seconds, while de-identified data can be automatically uploaded for public health surveillance.Our platform’s technology eliminates the need for bulky (often expensive) laboratory equipment and technicians, and resolves the slow reporting of results and crippling supply chain risks that have plagued PCR-based testing. Likewise, our platform overcomes the inaccuracy and lack of sensitivity which often limit the utility of lateral flow serology assays. Pinpoint’s COVID-19 test does not require a laboratory, specially-trained technicians, sample purification, or sample amplification. The assay’s disposable cartridges, low-cost reader and mobile application are user-friendly and simple enough to be used properly by everyone from untrained consumers to healthcare workers.

V4C is creating the next-generation of mRNA vaccines capable of activating cytological T cells. The initial target is a vaccine against the four serotypes of dengue virus, which has a critical need for this innovative technology to eliminate the risk of antibody dependent enhancement (ADE) of disease.- Support operations, international development, relationship building, and strategic vision for development of innovative mRNA vaccines targeting infectious diseases of the most vulnerable populations (e.g., dengue virus);- Guide development and execution of the company’s strategic and operating framework, creation of scientific advisory board, negotiate partnerships, and fundraising (VC and nondilutive) to support multidisciplinary activities at global sites, including Paris, Tokyo, New Delhi, Singapore, and San Francisco

- Consulting at both a hands-on and strategic level on emerging infectious diseases, evaluation of biotechnologies, global health, health systems strengthening, and biosafety and biosecurity (BS&S), providing creative solutions to complex analytical and operational problems requiring critical thinking and technical breadth- Aiding large global nonprofits (e.g., PATH and GAVI) and private research/biotech companies in evaluating the current competitive/operational landscape, strategically aligning their technical expertise and tools with existing gaps, understanding on-the-ground needs, and developing short- and long-term strategic plans- International scientific mentoring, training, in-country national human and veterinary laboratory readiness preparation, and capacity building in BS&S and emerging and neglected infectious diseases

- Contribute to thought leadership and support development and execution of Global Health growth strategy

- Advise on scientific strategy for a public benefit corporation focused on improving access to diagnostics by developing health solutions for everyone, especially historically underserved and underrepresented groups

- Oversaw the company’s scientific organization, laboratory teams, and all aspects of R&D, including operations, performance, ideation/discovery, development, validation, and regulatory clearance of product portfolio (over 20 new laboratory developed tests brought online and 4 new commercial products developed);- Built and maintained strategic partnerships to support scientific growth and revenue generation around the company’s core mission to develop an end-to-end home-based solution for STI prevention, detection, and treatment via integration of telehealth, self-collection kits, CLIA laboratory, and online pharmacy

- Led scientific development and integration, building teams of scientific and technical staff, leveraging team member’s skills, to support cross enterprise objectives in international biosurveillance and biosecurity/biosafety- Identified, developed, maintained, and directed the activities of technical teams to advance products and programs (generating >$20m in revenue); selecting, cultivating, and collaborating with technical personnel to ensure the efficient capture of new funding and expansion of existing projects- Facilitated development of a product focused on global health threat detection and modeling, and comprehensive risk analytics; the proprietary datasets, modeling and analytic tools, and a software platform with the capabilities to track, model, and forecast epidemics and associated risks and impacts was acquired by Ginkgo Bioworks- Planned and managed scientific activities of 8 international field teams, composed of local and expatriate scientists, engaged in building capacity, deploying innovative methods for infectious disease detection, reporting and responding to disease outbreaks within human and veterinary health systems in Southeast Asia and Africa- Directed projects to develop and oversee metagenomic analysis technologies internationally- Developed, executed, and evaluated operational plans and budgets (>$6m annually) for global programs, requiring close coordination with host country governments and USG stakeholders- Global technical director for international laboratory teams that successfully established sites in 8 countries and completed 150k diagnostic tests for >25 pathogens, resulting in the detection of over 1,000 distinct viruses- Provided strategic direction to the USAID PREDICT program in coordination with partner leads to facilitate pathogen discovery, laboratory sciences, and technology development globally for detection of emerging pathogens and an early warning of potential biological threats

- Provide scientific consulting services to both the US Government and private sector entities on biodefense, emerging infectious diseases, and outbreak response.- Assessment and implementation of international health regulations (IHR) competency for a national rapid response team in former Soviet states.- Training of forward teams in developing countries on highly pathogenic sample collection, transport, and analysis.

Virus Pathogenesis Unit:- Manage and coordinate a project to generate a simplified experimental system to identify human genetic factors that affect susceptibility to severe forms of dengue disease.- Advisor on various aspects of arthropod-borne virus transmission, pathogenesis, and research strategies, as well as serving as a scientific reviewer for multiple biomedical journals.- Negotiate scientific collaborations in institutional, domestic, and international settings.

- Conceived of and led a research project that has productively expanded the understanding of the early immune response to naturally transmitted malaria infection.- Successfully represented the group at multiple domestic and international biomedical and public health meetings.

- Certified and granted FBI/DOJ clearance to work with highly pathogenic viruses and select agents. - Served in an advisory role as member of academic, ethics, and recruitment committees. - Planned, conducted, presented, and published scientific research on pathogenesis of emerging mosquito-borne viruses. - Led the Experimental Pathology Graduate Association and coordinated collaborations between various laboratories.

- Established a model that determined the probability of infection with Lyme disease following exposure to infected ticks, and expanded understanding of the early pathogenesis of Lyme disease and transmission cycles that culminated in the testing of a novel community-based approach to decreasing tick-transmitted disease prevalence.- Facilitated collaborations between the Bacterial Zoonosis Branch and biotech industry and international U.S. military laboratories situated in developing countries.- Designed diagnostic assays for detection of possible bioterrorism agents and trained as a member of a bio-response deployable laboratory team.